Inveready et al. invest €380k in Proretina
Inveready, Corporación CAN, Clave Mayor and Sodena have teamed up to invest €380,000 into Proretina Therapeutics as part of a capital increase.
The four private equity firms each invested €95,000 in the company, which develops pharmaceuticals for the treatment of diseases affecting the retina.
The deal meant each of the investors increased their equity stake from 8.6% to 12.5%.
The unquote" team is currently researching this transaction. In-depth deal information for subscribers will follow shortly.
If you have any information regarding this transaction, please contact Susannah Birkwood on +44 20 7004 7524 or susannah.birkwood@incisivemedia.com
More on Southern Europe
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater
EU FSR could impact PE fundraising with potential rise in ‘clean funds’
FSR could lead GPs to create funds without foreign LPs; red tape around sovereign wealth funds likely
Letter from the editor: Unquote is moving to Mergermarket
Unquote Editor Harriet Matthews outlines Unquote.com's upcoming move to the Mergermarket platform and the new capabilities and intelligence that this brings to Unquote readers
GP Profile: Apheon builds on family roots, mulls exits and reinvestment opportunities
Belgian GP, formerly known as Ergon, to continue to target family- and entrepreneur-owned European businesses
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater